JP2015519347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519347A5 JP2015519347A5 JP2015514191A JP2015514191A JP2015519347A5 JP 2015519347 A5 JP2015519347 A5 JP 2015519347A5 JP 2015514191 A JP2015514191 A JP 2015514191A JP 2015514191 A JP2015514191 A JP 2015514191A JP 2015519347 A5 JP2015519347 A5 JP 2015519347A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- receptor
- disorder
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 229930003827 cannabinoid Natural products 0.000 claims description 30
- 239000003557 cannabinoid Substances 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 27
- 102000005962 receptors Human genes 0.000 claims description 27
- 108020003175 receptors Proteins 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100033061 G-protein coupled receptor 55 Human genes 0.000 claims description 2
- 101000871151 Homo sapiens G-protein coupled receptor 55 Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- -1 aminocarbonyl (carbamoyl) Chemical group 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000030266 primary brain neoplasm Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 239000000126 substance Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651961P | 2012-05-25 | 2012-05-25 | |
| US61/651,961 | 2012-05-25 | ||
| US201361789629P | 2013-03-15 | 2013-03-15 | |
| US61/789,629 | 2013-03-15 | ||
| PCT/US2013/042457 WO2013177418A1 (en) | 2012-05-25 | 2013-05-23 | Methods of regulating cannabinoid receptor activity-related disorders and diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519347A JP2015519347A (ja) | 2015-07-09 |
| JP2015519347A5 true JP2015519347A5 (OSRAM) | 2016-09-29 |
| JP6130495B2 JP6130495B2 (ja) | 2017-05-17 |
Family
ID=48577922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514191A Active JP6130495B2 (ja) | 2012-05-25 | 2013-05-23 | カンナビノイド受容体活性関連障害及び疾患を調節する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US20150157580A1 (OSRAM) |
| EP (1) | EP2854855B1 (OSRAM) |
| JP (1) | JP6130495B2 (OSRAM) |
| AU (1) | AU2013266235B2 (OSRAM) |
| CA (1) | CA2874655C (OSRAM) |
| WO (1) | WO2013177418A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3125878A4 (en) * | 2014-04-03 | 2017-11-29 | Mitchell Woods Pharmaceuticals, Inc. | Methods of treating breast cancer |
| US20180042867A1 (en) * | 2015-03-06 | 2018-02-15 | Mitchell Woods Pharmaceuticals, Inc. | Methods of treating cancer |
| EP3356833A4 (en) * | 2015-09-30 | 2019-04-10 | Bird Rock Bio, Inc. | ANTIBODIES FOR BINDING HUMAN CANNABINOID RECEPTOR 1 (CB1) |
| US20180271808A1 (en) * | 2015-10-01 | 2018-09-27 | Mitchell Woods Pharmaceuticals, Inc. | Methods of reducing chemoresistance and treating cancer |
| US11782050B2 (en) | 2017-09-19 | 2023-10-10 | Cannametrix, Llc | Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof |
| US11487195B2 (en) | 2018-04-26 | 2022-11-01 | Wonder Vision Techno Laboratory Co., Ltd. | Dome screen, dome screen projection apparatus, and method for fabricating the same |
| CN109942462B (zh) * | 2019-03-06 | 2022-01-14 | 宏冠生物药业有限公司 | 一种盐酸班布特罗的合成工艺 |
| JP7532754B2 (ja) * | 2019-09-04 | 2024-08-14 | 株式会社ニコン | 画像解析装置、細胞培養観察装置、画像解析方法、及びプログラム |
| GB202302225D0 (en) * | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352806A (en) | 1992-04-17 | 1994-10-04 | Abbott Laboratories | Taxol derivatives |
| US5912264A (en) | 1997-03-03 | 1999-06-15 | Bristol-Myers Squibb Company | 6-halo-or nitrate-substituted paclitaxels |
| AR030188A1 (es) | 2000-02-02 | 2003-08-13 | Univ Florida State Res Found | Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos |
| SI1767535T1 (sl) | 2002-08-23 | 2010-03-31 | Sloan Kettering Inst Cancer | Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh |
| EP1595146B1 (en) * | 2003-02-18 | 2008-04-23 | AstraZeneca AB | Screening assays for cannabinoid-ligand-type modulators of gpr55 |
| AU2007286051B2 (en) | 2006-08-10 | 2013-01-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure |
| EP2515946B1 (en) * | 2009-12-23 | 2019-05-22 | The Board of Trustees of the University of Illionis | Nanoconjugates and nanoconjugate formulations |
| WO2011112867A1 (en) | 2010-03-10 | 2011-09-15 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas |
-
2013
- 2013-05-23 EP EP13727753.9A patent/EP2854855B1/en active Active
- 2013-05-23 US US14/403,516 patent/US20150157580A1/en not_active Abandoned
- 2013-05-23 CA CA2874655A patent/CA2874655C/en active Active
- 2013-05-23 AU AU2013266235A patent/AU2013266235B2/en active Active
- 2013-05-23 JP JP2015514191A patent/JP6130495B2/ja active Active
- 2013-05-23 WO PCT/US2013/042457 patent/WO2013177418A1/en not_active Ceased
-
2016
- 2016-08-01 US US15/225,643 patent/US10130593B2/en active Active
-
2018
- 2018-09-12 US US16/129,569 patent/US10485771B2/en active Active
-
2019
- 2019-10-11 US US16/600,234 patent/US10772849B2/en active Active
-
2020
- 2020-08-13 US US16/992,742 patent/US11389415B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519347A5 (OSRAM) | ||
| JP6342805B2 (ja) | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 | |
| US10166246B2 (en) | TGR5 agonist complexes for treating diabetes and cancer | |
| JP2019516711A5 (OSRAM) | ||
| JP2011057693A5 (OSRAM) | ||
| JP2014505008A5 (OSRAM) | ||
| JP2019501133A5 (OSRAM) | ||
| JP2013522230A5 (OSRAM) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2013526544A5 (OSRAM) | ||
| JP2015511638A5 (OSRAM) | ||
| JP2013509429A5 (OSRAM) | ||
| JP2015536964A5 (OSRAM) | ||
| JP2015508103A5 (OSRAM) | ||
| JP2016515628A5 (OSRAM) | ||
| JP2015536997A5 (OSRAM) | ||
| JP2013509411A5 (OSRAM) | ||
| TWI462908B (zh) | 用於治療增生性失調症的化合物 | |
| JP2014533272A5 (OSRAM) | ||
| JP2008535785A5 (OSRAM) | ||
| JP2019532047A5 (OSRAM) | ||
| JP2014512355A5 (OSRAM) | ||
| McShane et al. | Updates on managing advanced breast cancer with palbociclib combination therapy | |
| JP2014530181A5 (OSRAM) | ||
| JP2010540649A5 (OSRAM) |